Lido Advisors, LLC Relmada Therapeutics, Inc. Transaction History
Lido Advisors, LLC
- $31.4 Billion
- Q3 2025
A detailed history of Lido Advisors, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Lido Advisors, LLC holds 13,905 shares of RLMD stock, worth $54,924. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,905
Previous 13,905
-0.0%
Holding current value
$54,924
Previous $8,000
237.5%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RLMD
# of Institutions
51Shares Held
7.88MCall Options Held
84.3KPut Options Held
0-
Ikarian Capital, LLC Dallas, TX1.84MShares$7.28 Million0.58% of portfolio
-
Driehaus Capital Management LLC Chicago, IL740KShares$2.92 Million0.01% of portfolio
-
Boothbay Fund Management, LLC New York, NY693KShares$2.74 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA583KShares$2.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$2.26 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $113M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...